← Back to Clinical Trials
Recruiting NCT00026650

NCT00026650 Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00026650
Status Recruiting
Phase
Sponsor National Cancer Institute (NCI)
Condition Cancer
Study Type OBSERVATIONAL
Enrollment 700 participants
Start Date 2000-02-14
Primary Completion

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 120 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 700 participants in total. It began in 2000-02-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

BACKGROUND * This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our participants, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols. * It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PDT, radiation modifiers, intraoperative radiotherapy, etc. OBJECTIVE -The primary objective of this protocol is to assess the late effects of treatment and the natural history of disease through collection of data from any standard procedures performed as part of follow up care on participants previously treated with radiotherapy. ELIGIBILITY -Participants who received radiation therapy. DESIGN * This is a natural history protocol in which long-term follow up data will be collected from participants who received radiation therapy. * It will be made clear to participants in the consent form, that data collected during their follow-up may be used anonymously for publications concerning the natural history of disease processes and long-term effects of treatment.

Eligibility Criteria

* INCLUSION CRITERIA: ROB investigator deems that it is in the best interests of the participant and the NCI/ROB for the participant to be seen in follow-up in the ROB clinic. Participant is able to provide informed consent. Participant must have a primary physician in the community to whom records and appropriate follow-up management can be given. Social services will be enlisted for any participants who lack health insurance, etc. Participants who have received radiotherapy. Age greater than or equal to 18 years of age EXCLUSION CRITERIA: Participants who are on an interventional research protocol at NIH at the time of enrollment.

Contact & Investigator

Central Contact

Rukayat O Salau

✉ rukayat.salau@nih.gov

📞 (240) 858-3712

Principal Investigator

Kevin A Camphausen, M.D.

PRINCIPAL INVESTIGATOR

National Cancer Institute (NCI)

Frequently Asked Questions

Who can join the NCT00026650 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00026650 currently recruiting?

Yes, NCT00026650 is actively recruiting participants. Contact the research team at rukayat.salau@nih.gov for enrollment information.

Where is the NCT00026650 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT00026650 clinical trial?

NCT00026650 is sponsored by National Cancer Institute (NCI). The principal investigator is Kevin A Camphausen, M.D. at National Cancer Institute (NCI). The trial plans to enroll 700 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology